Xin Xu

Optimization of vonoprazan‐amoxicillin dual therapy for eradicating <i>Helicobacter pylori</i>infection in China: A prospective, randomized clinical pilot study

Yi Hu, Xin Xu, Yaobin Ouyang et al. · Helicobacter · 2022 · 57 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

Yi Hu, Xin Xu, Xiao‐Shun Liu et al. · Frontiers in Immunology · 2023 · 40 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Early prediction of carbapenem-resistant Gram-negative bacterial carriage in intensive care units using machine learning

Qiqiang Liang, Qinyu Zhao, Xin Xu et al. · Journal of Global Antimicrobial Resistance · 2022 · 39 citations · Full text

Computing, Health Informatics, Infectious Diseases +17

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication

Yi Hu, Xin Xu, Yaobin Ouyang et al. · Frontiers in Cellular and Infection Microbiology · 2022 · 35 citations · Full text

Life Sciences, Microbiology, Pharmacology +15

Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial

Yi Hu, Zhenyu Zhang, Fen Wang et al. · The Lancet Microbe · 2024 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14